Yaroslav V. Shparyk
Lviv, Ukraine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Clinicopathological features of breast cancer in Ukrainian women with BRCA1 c.181T>G (p.Cys61Gly) variant: a case series.
Journal: Frontiers in endocrinology
Published: April 19, 2026
Different association of gBRCA1 and gBRCA2 variants with HER2-low status in invasive breast cancer: findings from a Ukrainian study.
Journal: Scientific reports
Published: May 02, 2025
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.
Journal: Frontiers in medicine
Published: January 09, 2025
Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial.
Journal: Breast (Edinburgh, Scotland)
Published: August 22, 2024
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: February 27, 2024
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Journal: Future oncology (London, England)
Published: November 02, 2023
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA network open
Published: April 06, 2023
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
Journal: The lancet. Gastroenterology & hepatology
Published: July 12, 2022
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Journal: Breast (Edinburgh, Scotland)
Published: June 22, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 01, 2021
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial.
Journal: Therapeutic advances in medical oncology
Published: July 27, 2021
Last Updated: 09/26/2026